NCT07451652 Low Dose Epcoritamab Plus GemOx in R/R DLBCL
| NCT ID | NCT07451652 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
| Condition | Relapsed/Refractory Diffuse Large B Cell Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-03-17 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2026-03-17 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Eligibility Criteria
Inclusion Criteria: * Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant * ECOG 0-2 * Women of reproductive age who agree on getting a contraceptive method * Subjects who fulfill Lugano´s criteria for disease activity * Subjects who voluntarily accept to participate in this study Exclusion Criteria: * Active bacterial, viral or fungal infection * Subjects who have already received an autologous o allogeneic stem cell transplantation * Subjects with other active neoplasias * Subjects with end-stage failure
Contact & Investigator
Perla R Colunga-Pedraza, MD
PRINCIPAL INVESTIGATOR
Hospital Universitario "Dr. José Eleuterio González"
Frequently Asked Questions
Who can join the NCT07451652 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Relapsed/Refractory Diffuse Large B Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07451652 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07451652 currently recruiting?
Yes, NCT07451652 is actively recruiting participants. Contact the research team at alrep_rcp@gmail.com for enrollment information.
Where is the NCT07451652 trial being conducted?
This trial is being conducted at Monterrey, Mexico.
Who is sponsoring the NCT07451652 clinical trial?
NCT07451652 is sponsored by Hospital Universitario Dr. Jose E. Gonzalez. The principal investigator is Perla R Colunga-Pedraza, MD at Hospital Universitario "Dr. José Eleuterio González". The trial plans to enroll 10 participants.